

Additional BMDS Dose-Response Models for Risk Assessment:

Quantal Models With Background Additive to Dose

*Quantal Models Reporting Dose-Response Function Slope With
Confidence Interval*

Multistage Weibull Time to Tumor Model

Disposition of Comments by External Reviewers

This document was drafted in July, 2007 and revised in mid-September, 2007, after EPA and Battelle conducted more testing and made necessary changes to some of the programs. The final revision was made in October-November, 2008, to address remaining questions about the MSW time to tumor model.

Background

Additional dose-response models for risk assessment constitute an FY07 APM (APM 493, MYP: HHRA LTG2).

NCEA-W, Quantitative Risk Management Group, undertook development of additional dose-response models of three types:

(1) versions of existing BMDS quantal models which have the background additive to dose, rather than additive to the response;

(2) versions of some frequently used BMDS quantal models (multistage, logistic, and log-logistic) that can report the slope of the dose-response function at a user-specified dose, with a confidence interval for the slope;

(3) a multistage Weibull time to tumor model.

Models with background additive to dose have been presented, discussed and analyzed mathematically in risk analysis literature. Adding these to the BMDS suite of models is thus a logical extension of BMDS capabilities, increasing analysts' ability to evaluate model uncertainty and to evaluate a wider range of models that may fit data well.

Adding the capability of quantifying the dose-response slope with a confidence interval is, at this stage, exploratory, and is expected to assist analysts in understanding the uncertainty attending 'extrapolation' from observed doses to lower doses.

The multistage Weibull time to tumor model requires data on time and context of tumor observations for individual animals. When such data are available, the model could provide more precise estimates than the BMDS 'cancer' (multistage) model. A time to tumor model accounts for the time course of tumor appearance and other sources of mortality over time, while the simpler quantal models use a count of tumors at the experiment's end (sometimes adjusted approximately for mortality differences among dose groups). Such data are occasionally available and have been used in some EPA risk assessments (e.g., those for 1,3-butadiene and dibromomethane). This software will estimate benchmark doses. A MSW time-to-tumor model of similar form was available commercially within "ToxRisk" software¹, which is now no longer commercially distributed or supported. The MSW software prepared by EPA differs substantially from ToxRisk.² It is simpler to use, but does not make any dose conversions or adjustments. It uses the profile likelihood method to find lower and upper confidence limits for a benchmark dose. (ToxRisk used an approximation which has some deficiencies under certain conditions).

¹ Toxicological Risk Assessment Program (1985) Developed by K. Crump, R. Howe, C. Van Landingham, and W. Fulton. Clement International Corporation, Ruston, LA, under contract to Electric Power Research Institute, Palo Alto, CA.

² EPA chose to develop software independently for a number of reasons, including the desire to thoroughly document software quality assurance, testing, and the associated theory and numerical methods.

Major Comments and EPA Responses

Comments are summarized by model type and then by major comment topics. Reviewers are cited below by initials: RK for Ralph Kodell, LR for Louise Ryan, WW for Webster West.

A. Dose-Response Slope and its Confidence Interval for Selected Quantal Models

1. Needs more testing to verify correctness of numerical results (WW).

Response: We believe the testing for this module was as thorough as that conducted for the background-dose modules (below). However, the documentation was unclear and has been revised to better demonstrate the thoroughness of our verification testing.

2. Need to evaluate coverage of confidence interval (WW), because this is a new implementation of profile confidence interval methods, rather than a simpler modification of existing BMDS code.

Response: We have done this for the multistage model, using a Monte Carlo method, documented in a separate report. The coverage is accurate.

3. Provide more detail about how SAS and Mathematica were used to verify results (LR).

Response: This has been done in the testing report. EPA has archived the verification programs with the testing report.

4. Confusing terminology in output file report from the models (RK).

Response: This has been changed to read (changes are in red-line):

```
-----
Slope Confidence-Interval Calculations
-----
Unconstrained Likelihood:   -372.7778112 (donlp3)
Chi-Square Boundary:       -374.6985416
Alpha:                      0.05000
Restrict Gamma [0,1]:      Yes

User-selected dose (d0):    150.0000000
Slope at d0:                0.0073267
Confidence Interval:        [0.0021002, 0.0139010]
```

and the User Guide has been modified accordingly.

B. Background Additive to Dose for BMDS Quantal Dose-Response Models

1. Complete the testing using some extreme cases (RK, LR, WW).

Response: We have done this, to verify numerical accuracy and 'graceful' handling of convergence failures and unusual results.

2. Restrictions on model parameters seem not always to be stated. Clarify distinction between cancer model and multistage in documents (RK). Why does the log-probit model have a constraint on the slope parameter to exceed one? (See Table 9 of background document. (LR)

Response: The model output reports do state restrictions, near the top. This comment may refer to the testing document or the user help files. In those documents, we have insured that parameter 'natural' restrictions are specified in a table and that they are discussed in the user help file. The user is referred to the Benchmark Dose Technical Guidance for advice on user-specified restrictions (e.g., coefficients non-negative and powers ≥ 1). We have added a brief note on consequences of parameters on boundaries, citing the Molenberghe and Verbeke paper (esp. in view of Dr. Ryan's observations about parameters on boundaries, see **D.1** below). We have clarified the distinction between the multistage and cancer models in our reports and in the user help file.

3. Change help-file language on dose-additive parameter to reflect the mechanistic motivation for this parameter (RK).

Response: This has been done to reflect Dr. Kodell's recommendations.

4. Logistic & probit models with new background response parameter - add discussion and guidance to user regarding the two-parameter (reduced) model, etc. (RK).

Response: Guidance to users will reflect Dr. Kodell's recommendations and the points mentioned in his comments. The user help file now states that a 2-parameter model (with parameters gamma and beta) can be fitted and compared to the current model with parameters alpha and beta, and to the 3-parameter model. [However, the scope of application is limited to response probabilities $> 50\%$ (including the control).]

5. Provide more detail about how SAS and Mathematica were used to verify results (LR).

Response: This has been done in the testing report. There was more in the Testing Document than in the background report cited by Dr. Ryan, but the testing report now provides more detail. EPA will also archive the verification programs with the testing report.

6. Convergence and identifiability issues (LR).

Response: We have created a report on convergence and identifiability issues, detailing the results of investigations by Battelle and EPA. This document is cited in the testing report. The user help file has been changed to reflect our current understanding of the practical limits on applying some of these models (log-logistic, log-probit, and Weibull with background dose parameter) perhaps with a heuristic explanation of the reasons. Battelle has conducted more testing to better identify the types of data associated with identifiability problems for these models.

7. Clarify explanations of new vs. current models. (LR).

Response: This applies to the User Help file and any background documents meant to provide an overview, comparing & contrasting old & new quantal models. We have modified this description to make it clearer.

8. Awkward and nonsensical discussion in Testing document. (LR)

Response: This has been corrected. Battelle has reviewed and edited the Testing and Methodology documents.

9. More detail about how parameter constraints are applied in maximum likelihood and confidence limit computation (discuss statistical implications as well as numerical methods). (LR)

Response: This has been addressed by revising the Methodology and Testing documents. (We believe the MSW documents already do this well.)

10. More detail in User Help file about constraints (multistage, esp.) and confidence limit computation. (LR)

Response: This is now addressed in a section titled Parameter Constraints. We cite key published papers, noting that Wald intervals are not asymptotically correct when a parameter is on a boundary of parameter space, but that likelihood-based confidence intervals for BMD and Extra Risk are asymptotically correct in this case.

11. Testing - compare new models to corresponding existing models by setting background parameter to zero for both (outcomes should then be identical). (WW)

Response: This has been done.

12. Initialize parameters at different starting points in the MLE and profile likelihood optimizations to be sure that the optimization result is unique and/or global. (LR, WW)

Response. This is done in the MSW time to tumor model software. It is not done in the BMDS quantal models. Doing so has its own liabilities, esp. in the profile likelihood optimizations. We have addressed this issue indirectly, by exploring the shape of the likelihood, and by evaluating coverage of the BMD confidence interval (see below).

13. Conduct further independent review of the software itself. (WW)

Response. At this point, the software has undergone internal and external review. The testing has been thorough and is well documented. We feel that further testing will not add value. However, for those modules that are released (and also those used internally for research), users will be advised that the modules are "beta" versions and they will be asked to comment on the model performance and especially to report any apparent errors or problems, for up to a year after release.

C. Multistage Weibull Time to Tumor Model

1. Use and Interpretation of parameter t_0 . (all) There were comments on the meaning and interpretation of t_0 , the lack of realism of making t_0 a constant, the fact that t_0 often occurs at a boundary of its parameter space, and estimability issues.

Response: EPA and Battelle staff had begun to question this model set-up and we expressed our reservations in the review documents. The reviewers' comments confirmed the need for a careful re-examination of the 'classical' MSW model, and were very helpful in directing our thoughts. Battelle examined these issues in a report to EPA in 2007.

(C.1.1) Interpretation of t_0

Based upon comments from reviewers, other experts consulted since review, and from the literature, we are confident that t_0 is a valid and estimable parameter in the MSW model for fatal tumors, and that it represents a time lag between when a tumor can just be detected (by the pathological methods used for the study) and death from the tumor. There was some unfortunate misunderstanding about interpreting t_0 because we used "onset" to describe the event "just detectable" in some of the written materials. This usage has been corrected.

It is important to recognize that parameter t_0 is used only in the model for Fatal tumors, thus for datasets having a mixture of Fatal and Incidental tumor contexts.

In practice, the MSW model for Incidental observations is more frequently applied, because analysts are interested in the earliest appearance of tumors, in which case parameter t_0 is not present in the model.

While the time lag represented by t_0 is in reality almost certainly a random variable, it is not clear that treating it as a constant sacrifices much accuracy or precision. The MSW model was developed by experts who were aware of this issue. The assumption seems reasonable as an approximation if the distribution of t_0 is narrow compared with the distribution of times being modeled (times of “onset” or of death).

(C.1.2) Correction of programming errors affecting estimated t_0

The reviewer reservations about the interpretation of t_0 were made in the context of some evidently unreasonable estimates for t_0 (which EPA called to the attention of the reviewers). Since the review, EPA and Battelle identified the cause and corrected the error (it was related to incorrect programming of the likelihood in connection with a constraint on t_0). The C code was revised to correctly estimate parameter t_0 , and the Methodology document was revised to correctly state the constraint for t_0 and to correctly represent the likelihood. Now, t_0 is constrained to be less than the smallest observed time for a Fatal tumor observation, and the likelihood contribution for an Incidental observation made at $t < t_0$ has been revised accordingly (the gradient and Hessian calculations also had to be revised).

Since these corrections were made, the MSW model gives plausible estimates (reasonably close to the true parameters) for Fatal tumors. EPA has tested MSW using large datasets produced by simulation (generating a mixture of Incidental, Fatal, and Censored observations) for which the true parameters are known. For non-fatal tumors (i.e., pure current-status data), the model has been providing plausible estimates from the start, and providing a parametric estimate that agrees closely with the nonparametric estimate given by `survfit(Surv(x, ...))` in S-Plus.

Thus, we now believe that the software is functioning well and giving correct estimates for both the MSW model for fatal tumors and the MSW model for incidental tumors.

(C.1.3) When estimates of t_0 may be unreliable

Insufficient data may prevent estimation of an accurate or meaningful value for t_0 , as described below. The User Help document (retitled “MSW Time-to-Tumor Model Description for Users”) has been updated to provide better guidance to users about this.

When the estimate of t_0 equals zero, then t_0 is estimated at a boundary of its parameter space. When t_0 equals the smallest observed time for a Fatal tumor observation, it equals a boundary implied by a constraint (which means that the support of the distribution depends on a parameter). In each of these cases, the Wald confidence intervals for parameters are no longer asymptotically accurate. More obviously, it means that the model for Fatal tumors may not be appropriate or the data may be insufficient to support

reliable inference. Thus, such ‘boundary’ estimates of t_0 must be interpreted as warnings to the user. The data and the estimated model must be compared numerically or graphically. The outcome of t_0 equal to zero implies a very rapidly fatal tumor, and that inference must either agree with the biological facts or be rejected (or at the very least, questioned and critiqued). When the estimate of t_0 equals the smallest observed time for a Fatal tumor observation, it is probably because the data are inadequate to support inference about the model for Fatal tumors. This outcome is also biologically questionable, because it implies that tumors can become pathologically detectable from the start of exposure (operationally, within the first week of study, assuming data are summarized by weeks).

Also, we have modified the “Description for Users” to recommend testing the sensitivity of MSW model predictions to the value of t_0 (by specifying a series of fixed values for t_0 in the software) under two conditions: (i) when estimated t_0 is at a boundary constraint, and (ii) when the standard error for t_0 (or the difference between BMD and BMDL) seem especially large. This was suggested by an EPA internal reviewer who has considerable experience with similar models.

Technical Comments from Battelle. In current versions of the software documentation, the interpretation of t_0 as the time between tumor “onset” and death from tumor is correct. Based on the derivation of the distribution function for tumor “onset” in item C4. below, the cumulative distribution function $F(t)$ for death from tumor at time t is equal to the probability from tumor “onset” by time $t - t_0$, i.e.,

$$F(t) = G(t - t_0) = 1 - \exp\{-(t - t_0)^c p(d)\}$$

The only way to interpret $F(t)$ as a time-to-“onset” distribution is to change, as Dr. Kodell suggests, the interpretation of t_0 to the one used traditionally for the location parameter in the 3-parameter Weibull distribution, i.e., the earliest possible time (after time 0) when tumor “onset” can occur. For non-fatal tumors, this change introduces an additional parameter which creates the same types of problems with estimation of t_0 as that seen in the multistage Weibull fatal tumor model. For the fatal tumors, death from tumor will no longer be a modeled tumor response, and the analysis will therefore be the same as for the non-fatal tumor model, except subjects categorized as Fatal (F) tumor context would be re-categorized as Incidental (I) tumor context. This nullifies the assumption that the censoring distribution is conditionally independent from the tumor “onset” distribution, and requires the censoring distribution to be specified in the model likelihood. In addition, by ignoring the additional information provided by the category for Fatal (F) and Unknown (U) tumor contexts, the statistical analysis is less powerful because the data are being “diluted”. We recommend that the original interpretation of $F(t)$ as a time-to-death (from tumor) distribution be retained within the software until sufficient time has been spent to properly investigate and understand the implications of such a change.

2. Parameter Constraints. (RK, LR) Not clearly stated.

Response: The parameter constraints are now clearly stated in the User Help File.

3. Testing. (a) Has MSW been tested for BMD calculation at times other than 104 weeks? (RK) (b) Test with more datasets and data configurations (WW). (c) It is also interesting that t_0 is estimated to be zero in every single case. Clearly, more diversity in this regard is desirable. (WW)

Response: (a) MSW has been tested for BMD calculation at times other than 104 weeks; as now described in the testing document. (b) This has been done. (c) In all examples provided, "t0" was fixed at zero, not estimated. We have added test results showing estimation of $t_0 > 0$.

4. Constraint on parameter "c". Dr. Kodell suggests that it may be appropriate to restrict "c" \geq number of dose-related stages ("k", the highest power of dose in the model). (RK)

Response. We understand the motivation and concepts behind this suggestion. We chose not to 'hard-wire' the software with such a restriction because (1) for most users, modeling is done for descriptive or predictive purposes, without positing a specific hypothesis about mechanism, and (2) users can implement Dr. Kodell's suggestion by using the MSW feature (similar to BMDS) that allows one to fix a parameter value. (Users could fix "c" at several values exceeding "k", to determine a value of "c" giving something near the maximum likelihood).

Technical Comments from Battelle. Dr. Kodell's interpretation of the shape parameter c as the total number of stages appears to be based on the derivation of the statistical multistage Weibull model from the physical multistage model for describing a particular mechanism in carcinogenesis. In the physical model, cancer develops by sequential stages of genetic cell mutation, and the hazard rate of transitioning from one stage to the next is assumed to be constant in time. If tumor "onset" occurs at stage c of the cell mutation process, and r_i is the hazard rate of transition from stage $i-1$ to stage i , then Armitage (1953) derives the hazard $h(t)$ of tumor "onset" at time t to be approximated by

$$h(t) = \prod_{i=1}^c r_i t^{c-1} / (c-1)!$$

provided that values of $r_i t$ are small. By definition of the hazard function, the probability $G(t)$ of tumor "onset" by time t (i.e., the cumulative distribution function for tumor "onset") is therefore

$$G(t) = 1 - \exp\left\{-\int_0^t h(\tau) d\tau\right\} = 1 - \exp\left\{-\prod_{i=1}^c r_i t^c / c!\right\}$$

For the multistage Weibull, the stagewise hazard rates r_i are assumed to be polynomials of dose d , so that $p(d) = \prod_{i=1}^c r_i(d) / c!$ is also a polynomial in d of some degree k . This explains Dr. Kodell's assertion of the shape parameter c (rather than k) as the actual number of stages. Under the additional restriction that the rates $r_i(d)$ are linear in d , the degree k is less than or equal to c , because some of the hazard rates could be constants. In light of this derivation, Dr. Kodell's recommendation of limiting $c \geq k$ and c as a positive integer makes sense. Nevertheless, before changing the software to account for these restrictions, some major preliminary steps are necessary. In particular:

- Certain performance features of the software (e.g., stability, efficiency) in its current capability would need to be improved, and
- The statistical and numerical implications of these new restrictions would need to be properly understood.

EPA response, continued: EPA has chosen not to modify the software to 'hardwire' these constraints, for the reasons noted above.

5. Initialize parameters at different starting points in the MLE and profile likelihood optimizations. (LR, WW)

Response. This is done in the MSW time to tumor model software.

6. The example output shown for the MSW model does not appear as well laid out as it might be. (RK)

Response. EPA has made some changes, and will continue to monitor user feedback on the layout and details of the printed output. The layout was designed to be similar to current BMDS output formats, with which many users are familiar.

7. Concerns related to the report "MSW Time to Tumor model description for users" (LR)

Response. Using the same letters as in Dr. Ryan's comments:

(a) The paragraph has been changed to be, we hope, unambiguous now. Non-fatal tumors require a different model (MSW model for non-fatal tumors), explained in the document. Dr. Ryan probably meant "how are Incidental tumors handled?", and that is now explained in the Methodology document. We have added to the section on Maximum Likelihood Estimation a passage explaining the likelihood contributions of observations with each context (C,I,F, and U), which should answer that question.

(b) (Dr. Ryan requested more detail about inference for t_0 when it is estimated to lie on a boundary). We have added suitable details. See also the response under (e).

(c) (Usage of “efficient estimators”). This passage has been corrected

(d) (Request to define “subject group” and make clear the origin of likelihood contributions) "Subject group" is now defined explicitly. The logic of the likelihood contribution for Incidental tumors is explained in the Methodology document and now in a new section added to the User Description (see (a) above). The User Description document notes the assumption of fixed t_0 . However, the model was developed and used by experts and the assumption seems reasonable as an approximation if the distribution of t_0 is narrow compared with the distribution of times being modeled (times of “onset” or of death). The likelihood contribution suggested by Dr. Ryan for Incidental observations is indeed used in the model for non-fatal tumors, but is not appropriate for modeling time to death from fatal tumors. In the latter case, an Incidental observation could be treated as left-censored (like a "C" observation), or treated as we did, as interval censored, with death from tumor predicted to occur between time t and $t+t_0$. Regarding the first term in the log-likelihood: $F(tjs, d)$ is increasing in tjs , so the suggested change would produce a negative likelihood component for Incidental tumors, i.e.,

$$F(tjs-t_0, d) - F(tjs, d) < 0.$$

To explain, for an incidental tumor context for fatal tumors at time t , tumor “onset” must have occurred some time between $t-t_0$ and t ; therefore, death from tumor must occur some time between t and $t+t_0$. The cdf $F(t, f)$ represents death from tumor by time t , the probability of death from tumor between t and $t+t_0$ is $F(t+t_0, d) - F(t, d)$

(e) (The section on BMDL computation is very terse. Also, more discussion is needed about how parameter restrictions affect inference) The description of BMDL computation is indeed terse. The language is modeled after that in the BMDS help files. However, this computation is explained in more detail in the Methodology document. Typical users would gain nothing from a detailed explanation. The current explanation should make sense to a user who has read another part of the BMDS user help files which explains two methods of solving for BMDL. The impact of parameter restrictions on inference is now explained in more detail. However, for the BMD confidence interval, we expect parameters on the boundary to have no effect on the 2-sided confidence interval coverage for the BMD, and we provide a warning about 1-sided (BMDL) coverage based upon our studies of the multistage quantal model.

8. Concerns related to the “MSW Time to Tumor model description for users” (WW). A bit heavy on mathematical detail, a bit light on implementation tips.

Response. We have added more on implementation that should help the user. For the data format, the user is directed (at the beginning of this document) to another document titled "User Guide", which gives instructions for running the program and assembling data files. We have combined the two documents into one "User Guide". We will continue to improve this document based on feedback from users.

9. “Documentation on issues that are more closely aligned to statistical concepts is often poorer” (LR).

Response. Dr. Ryan’s statement appears to criticize an apparent lack of exposition on statistical issues. Dealing with statistical issues is complicated by the facts that:

- The multistage Weibull model (for fatal tumor) fails to satisfy the standard regularity conditions for asymptotic normality of maximum likelihood estimators, because the support of the likelihood over the t_0 parameter is dependent on the data (and the Fisher information is not finite if shape parameter $c \leq 2$), and
- Time-to-tumor experiments are subject to a complex censoring scheme based on tumor contexts.

In a broad sense, Chapter 7 of the multistage Weibull Time-to-Tumor Methodology Description document covers some of the issues, but a significant effort of theoretical research would be necessary to provide more detailed insight. Nevertheless, Dr. Ryan’s concerns about parameter estimates that end up on the boundary of the parameter space (although not specifically directed at just the multistage Weibull model) are important and have been addressed in more detail the documentation.

10. Specification of (t-t0) term in the model. (LR).

Response. Dr. Ryan suggests that the definition of the distribution function associated with the multistage Weibull should be simplified by replacing $(t - t_0)^c$ with $(t - t_0)_+^c$, and states, *“I don’t think it is correct to simply say that there is a restriction that $t > t_0$ ”*. Our restriction was based on the statistical literature for the 3-parameter Weibull distribution, where the location parameter is commonly restricted in this way. Dr. Ryan’s objection may be based on a semantic difference in the interpretation of the location parameter between the multistage and 3-parameter Weibull models. After examining the two options, we have concluded that Dr. Ryan’s definition of the distribution function is correct and we have adopted it.

Both the software and documentation have been changed to implement the revised definition for the distribution function.

A particular benefit can be seen with the parameter t_0 . In our original definition, the parameter space for t_0 was bounded above by the minimum observation time in the data (except for observations with tumor contexts C). This was puzzling, because a parameter describing a feature of the tumor response (time between “onset” and death from tumor) was being constrained by the censoring mechanism (sacrifice or premature death); however, the censoring mechanism was supposed to be independent from the tumor response. Dr Ryan’s definition removes this constraint, and limits the MLE for t_0 to lie somewhere between 0, and the minimum observation time for fatal (F) tumor contexts. (This restriction, in turn, is consistent with the assumption that subjects are tumor-free at time 0).

D. Comments that Apply Generally to BMDS Models (as well as the models under review).

1. Parameter constraints; parameters at boundaries. There is a need to deal with statistical issues related to parameters on boundary of parameter space. (e.g., coefficients equal to zero), which complicates statistical inference for confidence intervals (LR).

Response:

Fortuitously, NCEA-W staff were aware of this issue and developing ways to deal with it before this review began. We have read the two cited papers and all others we could find that pertain to this issue. This issue pertains to dose-response modeling generally, not merely to BMDS models (it applies very generally to hypothesis testing for linear and nonlinear models). How we are dealing with this matter is discussed in two parts below.

(Part i) The theory of Self and Liang (1987) requires specialization to our dose-response models. After that mathematical foundation is laid, numerical evaluations of coverage are needed for profile-likelihood confidence intervals and for the Self-Liang adjustment to Wald intervals. This will allow us to quantify the coverage when one or more parameters are on a boundary, and will provide evidence to support practical measures or advice applicable to BMDS.

We have accomplished much of this objective already. Dr. Bimal Sinha (University of Maryland - UMBC) has made considerable progress on these matters, working with EPA under a fellowship at NCEA-W. A first report, laying out the application of methods to the multistage model, is published as a technical report (http://www.math.umbc.edu/~kogan/technical_papers/2007/Sinha_Kopylev_Fox.pdf) and a revised version will later appear as a publication of Indian Statistical Institute. Numerical evaluations of coverage for the multistage quantal model were published recently.³ Other papers are in various stages of preparation or review.

All of this work applies, at present, only to the multistage model, which is important because it is used so frequently in cancer dose-response modeling. The general conclusions apply to other models, however, as we have noted in the publications cited above and in the revised User Help files and other documentation.

(Part ii) We are providing suitable information and advice to typical users of dose-response models and BMDS. We have provided suitable text in the BMDS help file that accompanies the new quantal models with background additive to dose, and in the MSW Description for Users (retitled Directions for Users). We have published one article in a widely read risk analysis journal,³ and we are preparing another, more applied paper, to make these issues and changes known to the wider community of risk assessment professionals who use dose-response models.

³ Kopylev, L., and Fox, J. (2008), "Parameters of a dose-response model are on the boundary. What happens with BMDL?" Risk Analysis, in press, published online 19 Oct. 2008.

The bottom line is that, although confidence intervals for model coefficients are adversely effected when a parameter is on a boundary, the BMD and Extra Risk (or Added Risk) are always interior to their parameter space and their likelihood ratio test statistics (2-sided) are asymptotically distributed as Chi-square(1). This conclusion is developed rigorously in Dr. Sinha's paper. EPA plans to conduct further evaluations of the practical implications. We conducted Monte Carlo evaluations of BMD confidence interval coverage to verify that the BMDS multistage quantal model achieves the nominal coverage with huge sample sizes ($n=100,000$), and to see how the coverages (1 and 2 sided) behave for typical sample sizes (see footnote 3, above).

2. Monte Carlo (simulation) studies in which empirical data are repeatedly generated from a known true model and then the results of fitting various models compared to the expected true values (LR, WW).

Response:

This would be a major undertaking, which we do not have the resources for currently. However, the studies described just above (for the multistage model, see footnote 3, above) accomplish this objective in part, by checking on the distribution of the benchmark dose and extra risk and parameter estimates.

Dr. Ryan also suggested that the Figures in the User Help file (for the quantal models) would be more informative if based on simulations (Monte Carlo). In our experience, this would be appreciated by statisticians but would confuse the typical user. It might be useful to create a technical report on Monte Carlo studies with suitable illustrations.

We evaluated confidence interval coverage for the BMD for the BMDS multistage quantal model (and to a lesser extent, the log-logistic model), using a Monte Carlo approach (see footnote 3, above). Results show 2-sided coverages close to nominal ($1-\alpha$), but 1-sided coverages (that is, for the BMDL) can vary between $1-\alpha$ and 1, depending upon the true model.

We have made considerable progress in evaluating coverage for the BMD confidence interval and publishing the results. We have yet to evaluate bias for the estimates of BMD and extra risk under various conditions and are suspending additional work pending the reception of our published work on coverages and presentations at several conferences.

3. Explore likelihood surface for multiple local maxima, esp. at boundaries of parameter space (WW). [this is related to reviewer (LR, WW) suggestions to incorporate multiple starting values for optimizations in maximum likelihood and confidence interval computations]

Dr. West observed: *The likelihood surfaces for the dose response models to be fit are extremely bumpy with sometimes peculiar boundary behavior for the common designs used. For example, with the multistage model, there are frequently values along the β_1 axis (where $\beta_2=0$) and values along the β_2 axis (where $\beta_1 = 0$) that provide roughly the same value of the likelihood function.*

Response: This is a novel observation that deserves thorough documentation. We have not committed EPA resources to such exploratory work, because we have not yet been able to observe this sort of likelihood surface, although EPA staff and Battelle have graphically explored likelihood surfaces for quantal models, esp. the log-logistic model, in the course of investigating convergence difficulties.⁴ At one time, we thought that we had observed such a surface for the MSW time to tumor model. However, revisions and corrections to the MSW model for time to tumor (noted above) appear to have eliminated the irregular, multi-modal likelihood profile curve we observed for an earlier implementation of the model for fatal tumors

Battelle was asked to evaluate Dr. West's comments and suggestions about exploring the likelihood surface using a grid and their response appears just below).

Exploration of the likelihood is also pertinent to Dr. Ryan's comments about identifiability. For some data configurations, the log-logistic model with background additive to dose shows a very shallow 'ridge' in the log-likelihood surface, and the maximum likelihood search stops short of the MLE. In such cases, the parameter standard errors (i.e., information matrix diagonal elements) may be very large, and parameter correlations may be essentially +/- 1. A warning about such indications of near-non-identifiability has been added to the User Help File (although the log-logistic model with background additive to dose is not being released, the other models can exhibit similar behavior for some datasets).

Response from Battelle: Dr. West expresses some concern on the reliability of model estimates from TOXRISK and proposes that multistage Weibull parameter estimates from BMDS be “*compared to the true optima in a number of test cases where the truth is determined by a complete grid search of the parameter space*” for purposes of testing to a better standard. In fact, the BMDS module for the multistage Weibull model selects starting values for estimating the model parameters by carrying out a complete grid search on two of the parameters and maximizing the likelihood over the remaining parameters. (Appendix C in the multistage Weibull Time to Tumor Methodology Description proves that the likelihood is concave over those remaining parameters.) Therefore, the BMDS module “globally” maximizes the multistage Weibull likelihood, under the assumptions that the search grid is sufficiently fine and the *donlp3* optimization is functioning properly. Therefore, a complete grid search seems unnecessary and is not recommended. While setting up a complete grid search may require only a couple of

⁴ "Convergence-Related Issues For Software Modules That Incorporate Background Dose/Response In Quantal Models Within Benchmark Dose Modeling Software (BMDS)," 24 pages, prepared by Douglas Mooney. Battelle report to EPA under EPA Contract Number EP-C-04-027, Work Assignment 3-08.

days to program, a single execution of a complete grid search may take a few hours to a day of execution time, depending on the number of stages in the model.